-
ATRX-Deficient Glioma and RTK Inhibitor Sensitivity
2026-09-14
The reference study identifies ATRX loss as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination experiments further show that RTK inhibition with temozolomide produces pronounced toxicity in ATRX-deficient models, supporting ATRX-aware interpretation of glioma drug studies and clinical trials.
-
Cy3 Goat Anti-Human IgG (H+L) Antibody Guide
2026-09-13
Turn human IgG binding into a measurable fluorescence signal across immunofluorescence, tissue imaging, flow cytometry, and ELISA. This guide shows how to use a Cy3 conjugated secondary antibody to compare orthopoxvirus antibody candidates while avoiding species-mismatch, background, and fluorescence-loss errors.
-
JXY, TLR4, and M1 Polarization in Colitis-Associated CRC
2026-09-12
Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting macrophages toward an M1-like inflammatory phenotype through TLR4-associated signaling. The study combines orthotopic disease modeling, tissue pathology, macrophage phenotyping, RT-qPCR, flow cytometry, and pharmacologic pathway perturbation to connect immune remodeling with reduced tumor burden.
-
Sisomicin Workflows for Antibacterial Research
2026-09-12
Build reproducible Sisomicin assays around concentration-response testing, time-kill confirmation, and resistance-aware controls. This workflow also adapts outcome-selection lessons from burn antiseptic research without overstating what clinical wound evidence can prove about an aminoglycoside antibiotic.
-
DAF-2 Diacetate: Mapping NO in Nodule Senescence
2026-09-11
Sulfur-dependent control of reactive nitrogen species offers a compelling model for understanding soybean nodule senescence. This thought-leadership guide explains how DAF-2 diacetate can add spatial and temporal nitric oxide data to the genetic, elemental, and physiological framework established by recent nodule research.
-
AngII, Cx43, and M1 Macrophage Polarization
2026-09-11
The reference study shows that angiotensin II drives RAW264.7 macrophages toward a pro-inflammatory M1-like state through coordinated activation of connexin 43 and NF-κB signaling. Pharmacological inhibition of Cx43 or NF-κB reduced inflammatory markers, providing a mechanistic framework for studying connexin-dependent inflammation while highlighting important limits of an immortalized-cell model.
-
Lovastatin: Designing Causal Metabolism Assays
2026-09-10
Lovastatin is more than an HMG-CoA reductase inhibitor: it is a causal probe for separating cholesterol and isoprenoid-dependent biology. This article combines pathway-aware assay design with insights from floral meristem regulation to improve interpretation across cancer, inflammatory, and proliferation models.
-
O-propargyl-puromycin (OPP) Workflow Guide
2026-09-10
O-propargyl-puromycin (OPP) converts a short translation pulse into a measurable signal for protein synthesis measurement in cells. This guide applies OPP to B-cell immunology, mitochondrial stress studies, imaging, flow cytometry, and proteomics while emphasizing controls, normalization, and troubleshooting.
-
Sisomicin: From Ribosome Mechanism to Translation
2026-09-09
Sisomicin is more than a broad-spectrum aminoglycoside antibiotic: it is a useful translational probe for connecting 30S ribosomal engagement, reproducible MIC testing, resistance biology, and safety-aware infection models. This thought-leadership perspective interprets historical clinical-isolate data and converts it into a decision framework for contemporary antibacterial research.
-
Optimized GBA1 mRNA for Gaucher Disease Therapy
2026-09-09
The reference study develops a sequence-engineering strategy for human GBA1 mRNA by optimizing untranslated regions, codon usage, and poly(A) tails. Its cellular and mouse data indicate that lipid nanoparticle delivery can produce lysosome-localized glucocerebrosidase and measurable enzyme activity, while also defining important limitations for translation beyond enzyme replacement therapy.
-
Mycoplasma pneumoniae Resistance in Beijing, 2023
2026-09-08
A 2024 Frontiers study characterized antimicrobial susceptibility, molecular profiles, and clinical features of Mycoplasma pneumoniae isolates collected from children in Beijing between 2021 and 2023. Its central finding was universal in vitro resistance to erythromycin and Azithromycin, with a further rise in Azithromycin MICs in 2023, highlighting the value of combining susceptibility surveillance with resistance-genotype monitoring.
-
Kanamycin Sulfate: Designing Better Microbial Assays
2026-09-08
Kanamycin Sulfate is a water-soluble antibiotic whose value extends beyond routine microbial selection. This article presents an assay-design framework connecting bacterial protein synthesis inhibition with toxin-focused anti-infection research, using the CAPE study in Clostridioides difficile as a model for stronger experimental interpretation.
-
Cytochalasin B: Actin Workflow for S2 Entry Studies
2026-09-07
Cytochalasin B (NSC 107658) provides a reversible way to test whether actin dynamics support endocytosis, intracellular trafficking, or cell movement. This workflow translates findings from Spiroplasma eriocheiris-infected Drosophila S2 cells into practical assay design, controls, and troubleshooting guidance.
-
CFDA-SE: From Cell Division to Surfaceome Insight
2026-09-05
A translational framework for combining CFDA-SE-based proliferation histories with nanobody-TurboID surfaceome mapping to distinguish cell-state changes from cell-surface mechanism.
-
SD 169: Practical p38 MAPK Research Workflows
2026-09-05
SD 169 (indole-5-carboxamide) gives researchers a practical way to interrogate p38α/β signaling across inflammation, type 1 diabetes research, and nerve repair models. This workflow-focused guide combines ATP-competition controls, phosphatase-aware assays, and troubleshooting strategies for more interpretable results.